



UNICHEM
LABORATORIES LTD.

Fax No : 91 (22) 2678 4391 / 5198
Tel. No. : 91 (22) 66888333
Website : <http://www.unichemlabs.com>
CIN : L99999MH1962PLC012451.

Registered & Corporate Office : Unichem Bhavan, Prabhat Estate, S. V. Road, Jogeshwari (West), Mumbai-400102, INDIA.

25.7.2016

Department of Corporate Services
Bombay Stock Exchange Ltd.
Phiroze Jeejeebhoy Towers
Dalal Street,
Mumbai - 400 001

Mr. Hari K.
Asst. Vice President- Operations
National Stock Exchange of India Ltd
Exchange Plaza, Bandra- Kurla Complex
Bandra (East), Mumbai - 400 051

Ref: BSE Scrip Code: 506690 : NSE Symbol - UNICHEMLAB

Dear Sir,

Please find enclosed herewith the **REVISED** investor release of the Unaudited Financial Results of the Company for the first quarter ended June 30, 2016.

Please take the above on record.

For UNICHEM LABORATORIES LIMITED

N. N. Thakore

Neema Thakore
Head - Legal & Company Secretary



UNICHEM
LABORATORIES LIMITED

UNICHEM LABORATORIES LIMITED

Unichem Bhavan
Prabhat Estate, Off S.V.Road,
Jogeshwari (West),
Mumbai - 400 102.
Tel. No: +91 (22) 66 888 333
Fax. No: +91 (22) 267 843 91/ 5198
CIN: L99999MH1962PLC012451

Investor Release

Mumbai, Saturday July 23, 2016

Q1 FY17 – Financial Performance

Unichem Laboratories Limited Q1 FY 17 Standalone (Ind-AS Compliant)

Total Income from Operations – Rs. 342 crs

EBIDTA – Rs. 44.2 crs

Net Profit After Tax – Rs. 25.8 crs

Total Comprehensive Income After Tax – 25.5 crs



Key Highlights of Q1 FY17

- During the quarter 2 ANDAs were filed
- Cumulative filings of ANDAs stood at 38 of which 21 ANDAs are approved
- Cumulative filings of DMFs stood at 46
- The USA Subsidiary (Unichem Pharmaceuticals USA Inc), continues to show a robust sales growth, by growing ~ 30% for the quarter ended June 30, 2016 as compared to corresponding period of previous year
- The USA Subsidiary (Unichem Pharmaceuticals USA Inc) reported Profit After Tax of **USD 0.24 Million** for the quarter ended June 30, 2016, on the back of robust sales growth
- Growth of Domestic portfolio for MAT June'16 stood at 9.8% as against 10.6% of IPM(AWACS)
 - Growth of Chronic portfolio for MAT June'16 stood at 12.5% as against 13.6% of IPM(AWACS)
 - Growth of Acute portfolio for MAT June'16 stood at 4.6% as against 8.5% of IPM(AWACS)
 - NLEM portfolio for MAT June'16 showed a growth of 11.9% as against 5.1% of IPM(AWACS)
 - Non NLEM Portfolio for MAT June'16 showed a growth of 9.6% as against 11.2% of IPM(AWACS)
- Market share of Ampoxin Group (Therapy - Anti Infective) improves by 2.5% (AWACS MAT June'16)
- Market share of Losar Group (Therapy- CVS) improves by 1.7% and maintains its #1 rank (AWACS MAT June'16)



Financial Highlights: Quarter 1, FY 2017 (Ind-AS Compliant)

REVENUE

- The Company's standalone Revenue from Operations stood at Rs. 342 crs for the quarter ended June 30, 2016 as against Rs. 312.4 crs recorded during the corresponding quarter of the previous year, reflecting a growth of 9.5%
- Revenues from Domestic Formulations stood at Rs. 221.5 crs as against Rs. 196.9 crs in the same period last year showing a growth of 12.5%
- Revenues from International Formulations Business came in at Rs. 97.1 crs as compared to Rs. 83.3 crs in the corresponding quarter of previous year showing a growth of 16.7%
- Revenues from API business (Excluding captive consumption for formulation business) stood at Rs. 20.8 crs as against Rs. 27.8 crs in the same period of the previous year

EBIDTA

- The Company's EBIDTA for the quarter stood at Rs. 44.2 crs as against 42.9 crs in same quarter last year

PAT

- Net Profit After Tax before Other Comprehensive Income came in at Rs. 25.8 crs as against Rs. 28.9 crs in same quarter of previous year
- Total Comprehensive Income after Tax stood at Rs. 25.5 crs as against Rs. 29.4 crs in same quarter of previous year
- EPS-Diluted for the quarter stood at Rs. 2.83 (*corresponding period of previous year Rs. 3.19*)



Standalone Financials (Ind-AS Compliant)

| UNICHEM LABORATORIES LIMITED | | | |
|---|--------------------------------------|--------------------------------------|-------------|
| Analysis of Standalone results for Quarter ended 30th June, 2016. | | Figures in INR Lakhs | |
| Particulars | STAND ALONE FINANCIALS | | |
| | For three months ended June 30, 2016 | For three months ended June 30, 2015 | % Growth |
| Sales Income from Operations: | | | |
| Domestic Operations | | | |
| Formulations | 22154.2 | 19696.1 | 12% |
| API | 295.3 | 656.6 | -55% |
| International Operations | | | |
| Formulations | 9714.6 | 8327.9 | 17% |
| API | 1779.7 | 2127.2 | -16% |
| Other Operating Income | 253.3 | 431.7 | -41% |
| Total Income | 34197.0 | 31239.6 | 9% |
| Expenditure: | | | |
| Material Consumption | 12384.4 | 11468.6 | 8% |
| % Sales Income | 36.2% | 36.7% | |
| Staff Cost | 6322.9 | 5479.9 | 15% |
| Other Expenditure | 11066.0 | 9999.2 | 11% |
| EBIDTA | 4423.7 | 4291.9 | 3% |
| % Total Income | 12.9% | 13.7% | |
| Finance Costs | 59.6 | 53.9 | 11% |
| Depreciation | 975.5 | 879.6 | 11% |
| Total Expenditure | 30808.5 | 27881.1 | 10% |
| % Total Income | 90.1% | 89.2% | |
| Operating Income | 3388.5 | 3358.4 | |
| % Total Income | 9.9% | 10.8% | |
| Other Income | 504.4 | 617.7 | -18% |
| Profit before Tax | 3892.9 | 3976.0 | -2% |
| % Total Income | 11.4% | 12.7% | |
| Income Tax | 1316.0 | 1077.0 | |
| Net Profit After Tax | 2576.9 | 2899.0 | -11% |
| % Total Income | 7.5% | 9.3% | |
| Other Comprehensive Income - Net of Tax | -22.3 | 37.60 | |
| Total Comprehensive Income after Tax | 2554.62 | 2936.65 | -13% |
| % Total Income | 7.5% | 9.4% | |
| Earning per Share (In Rupees) | | | |
| Basic | 2.84 | 3.19 | -11% |
| Diluted | 2.83 | 3.19 | -11% |



UNICHEM
LABORATORIES LIMITED

Subsidiaries:

Unichem Pharmaceuticals (USA), Inc., the 100% US Subsidiary clocked net sales of **USD 9.6 Million** for the quarter ended June 30, 2016 (*corresponding period of the previous year: USD 7.4 Million*) showcasing a healthy growth of ~ 30%. The subsidiary reported **Profit before Tax of USD 0.45 Million**. **Profit after Tax stood at USD 0.24 Million** for quarter ended June 30, 2016.

Niche Generics Limited, the 100% UK Subsidiary recorded net sales of **GBP 2.7 Million** for quarter ended June 30, 2016 (*corresponding period of the previous year: GBP 1.9 Million*) and Net Profit for quarter ended June 30, 2016 stood at **GBP 0.1 Million**.

Unichem Farmaceutica Do Brasil Ltda, the 100% Brazilian Subsidiary recorded net sales of **Brazilian Real 0.7 Million** for the quarter ended June 30, 2016 (*corresponding period of the previous year: Brazilian Real 0.5 Million*) and Net Loss of **Brazilian Real of 0.7 Million** for the quarter ended June 30, 2016.

Unichem SA (Pty) Limited, the 100% South African Subsidiary recorded net sales of **South African Rand 4.7 Million** for the quarter ended June 30, 2016 and Net Loss of **South African Rand of 0.1 Million** for the quarter ended June 30, 2016.



India Formulation Business

Key Highlights

AWACS

Domestic Formulation market for MAT June'16 is estimated at ~Rs. 100,017 crs {with bonus units at full value}, reflecting a growth of 10.6%. (AWACS)

Unichem Laboratories Limited's revenue is estimated at ~Rs. 908 crs (AWACS MAT June'16) and growing at 9.8% with a market share of approx 1% (in covered market approx 2%).

Brand Group Scenario – AWACS

| Products | MAT JUNE' 16 Val (crs) | % Growth | % Market Share | % Revenue Contribution |
|----------------|---------------------------|------------|-------------------|---------------------------|
| UNICHEM | 908 | 9.8 | 0.9 | 100.0 |
| LOSAR GROUP | 178 | 8.0 | 35.8 | 19.6 |
| AMPOXIN GROUP | 75 | 5.9 | 45.6 | 8.3 |
| UNIENZYME | 58 | -5.5 | 15.1 | 6.4 |
| TELSAR GROUP | 55 | 11.9 | 3.1 | 6.0 |
| OLSAR GROUP | 37 | 17.2 | 5.5 | 4.1 |
| VIZYLAC | 34 | 12.4 | 13.3 | 3.7 |
| PREGABA GROUP | 28 | 33.7 | 6.0 | 3.1 |
| TRIKA GROUP | 27 | -9.4 | 19.8 | 3.0 |
| SERTA | 23 | 13.6 | 28.8 | 2.5 |
| METRIDE GROUP | 20 | 6.9 | 0.8 | 2.2 |



UNICHEM
LABORATORIES LIMITED

Unichem Laboratories Brands Against Covered Market – AWACS

| MAT June'16 | Unichem Brand | | Covered Market | |
|----------------|---------------|------------|----------------|-------------|
| Top Brands | Size (Rs.Crs) | % Growth | Size (Rs.Crs) | % Growth |
| UNICHEM | 908 | 9.8 | 100,017 | 10.6 |
| LOSAR GROUP | 178 | 8.0 | 498 | 3.0 |
| AMPOXIN GROUP | 75 | 5.9 | 165 | -8.6 |
| UNIENZYME | 58 | -5.5 | 384 | 6.6 |
| TELSAR GROUP | 55 | 11.9 | 1768 | 20.8 |
| OLSAR GROUP | 37 | 17.2 | 672 | 12.5 |
| VIZYLAC | 34 | 12.4 | 254 | 15.7 |
| PREGABA GROUP | 28 | 33.7 | 473 | 20.6 |
| TRIKA GROUP | 27 | -9.4 | 136 | 0.8 |
| SERTA | 23 | 13.6 | 78 | 11.5 |
| METRIDE GROUP | 20 | 6.9 | 2438 | 16.5 |



UNICHEM
LABORATORIES LIMITED

About Unichem Laboratories Limited

Unichem Laboratories Limited is an international, integrated, specialty pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India and several other markets across the world. In India, the company is a leader in niche therapy areas of cardiology, neurology, orthopedics and anti-infectives. The company has strong skills in product development, process chemistry and manufacturing of complex API as well as dosage forms. More information about the company can be found at www.unichemlabs.com

For more information please contact:

Ms. Neema Thakore

Ph: +91-22-66888 404

E-mail: neema.thakore@unichemlabs.com

Mr. Rakesh Parikh/ Mr. Monish Shah

Ph: +91-22-66888 414

Ph: +91-22-66888 509

E-mail: rparikh@unichemlabs.com

monish.shah@unichemlabs.com

Disclaimer:

This press release includes forward-looking statements. We have based these forward-looking statements on our current expectations and projections about future events. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ serially. Such factors include, but are not limited to, changes in local and global economic conditions, our ability to successfully implement our strategy, the market acceptance of and demand for our products, our growth and expansion, technological change and our exposure to market risks. By their nature, these expectations and projections are only estimates and could be materially different from actual results in the future.